[
    {
        "pregunta": "1. What are the three diseases that comprise antineutrophil cytoplasmic antibody-associated vasculitides (AAV)?",
        "respuesta": "The three diseases that comprise antineutrophil cytoplasmic antibody-associated vasculitides (AAV) are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).",
        "contexto": [
            "2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis  unknown      A7FDDF976624E2E85584FDD8C00804F0 10.1002/acr.24634  INTRODUCTION The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases affect smalland medium-sized vessels",
            "(oral)</strong><br><strong>Varicella</strong><br><strong>Zoster</strong><br><strong>Yellow fever</strong> | <strong>Granulomatosis with polyangiitis</strong><br><strong>Microscopic polyangiitis</strong><br><strong>Eosinophilic granulomatosis with polyangiitis</strong><br><strong>Giant cell arteritis</strong><br><strong>Polyarteritis nodosa</strong><br><strong>Takayasu arteritis</strong><br><strong>Cryoglobulinemic vasculitis</strong><br><strong>Relapsing",
            "polyangiitis (EGPA). These diseases affect smalland medium-sized vessels and are characterized by multisystem organ involvement. GPA is characterized histologically by necrotizing granulomatous inflammation in addition to vasculitis. Common clinical manifestations include destructive sinonasal lesions, pulmonary nodules, and pauci-immune glomerulonephritis. GPA is most commonly associated with cytoplasmic ANCA and antibodies to proteinase 3 (PR3). Among European populations, prevalence ranges",
            "vasculitis</strong><br><strong>Relapsing polychondritis</strong><br><strong>Behçet's disease</strong><br><strong>Kawasaki disease</strong><br><strong>IgA vasculitis (Henoch-Schönlein)</strong><br><strong>Primary CNS vasculitis</strong><br><strong>Goodpasture's syndrome (anti-GBM)</strong><br><strong>Cogan's syndrome</strong><br><strong>Cutaneous small vessel vasculitis</strong><br><strong>Rheumatoid vasculitis</strong><br><strong>Urticarial vasculitis</strong> |",
            "populations has been estimated to range from 2 to 38 cases per million Prior to the use of alkylating agents, survival with these diseases was quite poor (e.g., median survival of patients with GPA was ~5 months) The Voting Panel was assembled for the ACR and Vasculitis Foundation's broad effort to develop recommendations for 7 forms of systemic vasculitis: giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, Kawasaki syndrome, and the 3 AAVs presented in this report. The physicians"
        ]
    },
    {
        "pregunta": "2. What is the recommended treatment for patients with active, severe GPA/MPA in terms of remission induction therapy?",
        "respuesta": "For patients with active, severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), remission induction therapy can include either rituximab or cyclophosphamide. Additionally, as part of the initial therapy, either intravenous (IV) pulse glucocorticoids or high-dose oral glucocorticoids may be prescribed. There are no trials that directly compare the efficacy of IV pulse glucocorticoids to high-dose oral glucocorticoids.",
        "contexto": [
            "Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies. Disease refractory to remission induction therapy is rare, and there are limited data to guide treatment recommendations. Practitioners should evaluate whether other conditions such as infection could be mimicking vasculitis. However, if a patient's disease",
            "<h2>| |Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.|Very low|</h2>\n\n<h1>Key recommendations for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)</h1>",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|",
            "<h1>Key recommendations for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA)</h1>",
            "induction therapies (i.e., plasma exchange as \"salvage\" or \"rescue\" therapy). Plasma exchange remains advisable in patients with GPA or MPA who also have anti-glomerular basement membrane disease. Ungraded position statement: For patients with active, severe GPA/MPA, either IV pulse glucocorticoids or high-dose oral glucocorticoids may be prescribed as part of initial therapy. There are no trials comparing the efficacy of IV pulse glucocorticoids to high-dose oral glucocorticoids. Higher doses"
        ]
    },
    {
        "pregunta": "3. What is the recommended treatment for patients with active, nonsevere GPA in terms of remission induction therapy?",
        "respuesta": "For patients with active, nonsevere granulomatosis with polyangiitis (GPA), the recommended remission induction therapy is to initiate treatment with methotrexate and glucocorticoids (GCs) over glucocorticoids alone. This recommendation is based on very low to moderate evidence.",
        "contexto": [
            "<h1>Key recommendations for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA)</h1>",
            "induction therapies (i.e., plasma exchange as \"salvage\" or \"rescue\" therapy). Plasma exchange remains advisable in patients with GPA or MPA who also have anti-glomerular basement membrane disease. Ungraded position statement: For patients with active, severe GPA/MPA, either IV pulse glucocorticoids or high-dose oral glucocorticoids may be prescribed as part of initial therapy. There are no trials comparing the efficacy of IV pulse glucocorticoids to high-dose oral glucocorticoids. Higher doses",
            "|Remission induction for active, nonsevere disease| | |\n|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate over cyclophosphamide or rituximab.|12, 13|Very low to moderate|\n|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate and GCs over GCs alone.|14|Low|",
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "<p>|Recommendation/statement|PICO question informing recommendation and discussion|Level of evidence|\n|---|---|---|\n|Remission induction for active, severe disease| | |\n|Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction.|4, 5, 6|Very low to moderate|"
        ]
    },
    {
        "pregunta": "4. What is the recommended remission maintenance therapy for patients with severe GPA/MPA?",
        "respuesta": "For patients with severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) whose disease has entered remission after treatment with cyclophosphamide or rituximab, it is conditionally recommended to use rituximab over methotrexate or azathioprine for remission maintenance. Additionally, methotrexate or azathioprine is recommended over mycophenolate mofetil or leflunomide for remission maintenance.",
        "contexto": [
            "|Remission maintenance| | |\n|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with rituximab over methotrexate or azathioprine for remission maintenance.|15, 16, 17, 18|Very low to moderate|",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over leflunomide for remission maintenance.|20|Very low to low|",
            "for remission maintenance. While there are limited data informing the use of remission maintenance therapy in EGPA, remission induction therapies (e.g., cyclophosphamide) should not be indefinitely continued given the potential toxicity. Thus, methotrexate, azathioprine, or mycophenolate mofetil can be considered for remission maintenance based on experience in GPA/MPA, expert opinion, and results from small studies Ungraded position statement: The duration of glucocorticoid therapy in EGPA",
            "Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies. Disease refractory to remission induction therapy is rare, and there are limited data to guide treatment recommendations. Practitioners should evaluate whether other conditions such as infection could be mimicking vasculitis. However, if a patient's disease"
        ]
    },
    {
        "pregunta": "5. How should patients with GPA/MPA who have experienced disease relapse with severe manifestations be treated?",
        "respuesta": "The provided information does not specifically address the recommended treatment for patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have experienced a disease relapse with severe manifestations. Therefore, I am unable to provide a reliable response based on the data available.",
        "contexto": [
            "<h1>Key recommendations for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA)</h1>",
            "<h2>| |Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.|Very low|</h2>\n\n<h1>Key recommendations for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)</h1>",
            "Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies. Disease refractory to remission induction therapy is rare, and there are limited data to guide treatment recommendations. Practitioners should evaluate whether other conditions such as infection could be mimicking vasculitis. However, if a patient's disease",
            "recommend prescribing medications for prophylaxis to prevent P jirovecii pneumonia. Prophylaxis to prevent P jirovecii pneumonia is discussed above in the GPA/MPA recommendations. The same considerations regarding prophylaxis to prevent this condition in patients with GPA/MPA apply to those with EGPA. DISCUSSION In this guideline, we present the first ACR/Vasculitis Foundation recommendations for the management of GPA, MPA, and EGPA. Although these recommendations provide a general guide for",
            "For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation. Low Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. Low Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.  Plasma exchange remains advisable in patients"
        ]
    },
    {
        "pregunta": "6. In what situations is rituximab preferred over cyclophosphamide for remission re-induction in patients with GPA/MPA?",
        "respuesta": "Rituximab is preferred over cyclophosphamide for remission re-induction in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance. Rituximab is more effective than oral cyclophosphamide for reinduction of remission among these patients, based on subgroup analysis of a randomized controlled trial.",
        "contexto": [
            "randomized controlled trial Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction. Multiple factors can influence whether rituximab or cyclophosphamide treatment (IV or oral) is used, such as time since last rituximab infusion and cumulative cyclophosphamide dose.",
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction. Rituximab is more effective than oral cyclophosphamide for reinduction of remission among patients who previously received cyclophosphamide and then experienced relapse, based on subgroup analysis of a randomized controlled trial Recommendation: For patients with GPA/MPA who",
            "|Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction.|29|Very low|\n|Treatment of refractory disease| | |",
            "|Treatment of refractory disease| | |\n|Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies.|30|Very low|</p>"
        ]
    },
    {
        "pregunta": "7. What is the recommended treatment for patients with severe GPA/MPA that is refractory to rituximab or cyclophosphamide for remission induction?",
        "respuesta": "For patients with severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) that is refractory to treatment with rituximab or cyclophosphamide for remission induction, the conditional recommendation is to switch treatment to the other therapy rather than combining the two therapies. It is important to note that disease refractory to remission induction therapy is rare, and limited data are available to guide these treatment recommendations. Practitioners should also evaluate whether other conditions, such as infection, could be mimicking vasculitis.",
        "contexto": [
            "Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies. Disease refractory to remission induction therapy is rare, and there are limited data to guide treatment recommendations. Practitioners should evaluate whether other conditions such as infection could be mimicking vasculitis. However, if a patient's disease",
            "|Treatment of refractory disease| | |\n|Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies.|30|Very low|</p>",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|",
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over leflunomide for remission maintenance.|20|Very low to low|"
        ]
    },
    {
        "pregunta": "8. What are the recommended therapies for patients with sinonasal, airway, and mass lesions in GPA?",
        "respuesta": "For patients with granulomatosis with polyangiitis (GPA) who have sinonasal involvement, the recommended therapies include nasal rinses and topical nasal therapies, such as antibiotics, lubricants, and glucocorticoids. These treatments may be beneficial, although the level of evidence supporting these recommendations is very low to low. Additionally, it is suggested to collaborate with an otolaryngologist with expertise in treating GPA to determine the use of these interventions. There is no specific information provided about therapies for patients with airway and mass lesions in GPA.",
        "contexto": [
            "<h1>Key recommendations for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA)</h1>",
            "<p>|PICO question informing recommendation and discussion|Recommendation/statement|Level of evidence|\n|---|---|---|\n|Treatment of sinonasal, airway, and mass lesions|Ungraded position statement: For patients with sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and GCs) may be beneficial.|Very low to low|",
            "For patients with sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and GCs) may be beneficial. 36, 37, 38, 39 Very low to low Recommendation: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, we conditionally recommend reconstructive surgery, if desired by the patient. Low Recommendation: For patients with GPA and actively inflamed subglottic and/or endobronchial tissue with stenosis, we conditionally",
            "that could influence whether plasma exchange is initiated include the patient's kidney function upon presentation, rate of loss of kidney function, response to remission induction therapies, and the patient's ability to tolerate serious infections. Recommendation/statement PICO question informing recommendation and discussion Level of evidence Treatment of sinonasal, airway, and mass lesions Ungraded position statement: For patients with sinonasal involvement in GPA, nasal rinses and topical",
            "sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and glucocorticoids) may be beneficial. We suggest collaborating with an otolaryngologist with expertise in treating GPA to determine whether these interventions should be used. Recommendation: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, we conditionally recommend reconstructive surgery, if desired by the patient. To optimize surgical outcomes,"
        ]
    },
    {
        "pregunta": "9. What considerations should be taken into account when dosing immunosuppressive therapy for patients with GPA/MPA?",
        "respuesta": "The provided information suggests that for patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), it is conditionally recommended against dosing immunosuppressive therapy based on antineutrophil cytoplasmic antibody (ANCA) titer results alone. This recommendation is based on very low-quality evidence. Therefore, dosing decisions should not rely solely on ANCA titers, and other clinical factors should be taken into account when managing immunosuppressive therapy in these patients.",
        "contexto": [
            "mass lesion with immunosuppressive therapy. 41, 42 Very low to low Other considerations Recommendation: In patients with GPA/MPA, we conditionally recommend against dosing immunosuppressive therapy based on ANCA titer results alone. Very low Recommendation: For patients with GPA who are receiving rituximab or cyclophosphamide, we conditionally recommend prophylaxis to prevent Pneumocystis jirovecii pneumonia. Low Recommendation: For patients with GPA/MPA in remission and stage 5 chronic kidney",
            "For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation. Low Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. Low Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.  Plasma exchange remains advisable in patients",
            "similar to those in patients receiving transplants for other reasons, with disease relapses in the transplanted kidney being rare Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. IVIG should not be used routinely to treat GPA/MPA (see above recommendation). However, in the rare instances in which patients with active disease may not be able to receive conventional immunosuppressive therapy",
            "<h2>| |Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.|Very low|</h2>\n\n<h1>Key recommendations for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)</h1>",
            "MPA, and EGPA. Although these recommendations provide a general guide for disease management, the patient's clinical condition, preferences, and values should influence their treatment. Overall, these recommendations reflect the evolving management of these diseases, including the new roles for biologic therapies and aggressive strategies to minimize glucocorticoid toxicity. The recommendations for GPA and MPA are supported by a greater number of randomized trials than are currently available"
        ]
    },
    {
        "pregunta": "10. What is the optimal duration of anticoagulation for patients with GPA/MPA who experience venous thrombotic events?",
        "respuesta": "The optimal duration of anticoagulation for patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who experience venous thrombotic events is unknown, as indicated by an ungraded position statement. Therefore, the information to provide a reliable response is not available.",
        "contexto": [
            "<h2>| |Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.|Very low|</h2>\n\n<h1>Key recommendations for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)</h1>",
            "disease may not be able to receive conventional immunosuppressive therapy (e.g., sepsis or pregnancy), IVIG can be used as a short-term intervention until conventional remission induction therapies can be used Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events. AAV is associated with an increased risk of venous thrombotic events, including both deep vein thromboses and pulmonary emboli Recommendations",
            "For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation. Low Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. Low Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.  Plasma exchange remains advisable in patients",
            "venous thrombotic events.  Plasma exchange remains advisable in patients with GPA or MPA who also have anti-glomerular basement membrane disease. Recommendation: In patients with active, severe GPA/MPA with alveolar hemorrhage, we conditionally recommend against adding plasma exchange to remission induction therapies. Two trials evaluated the use of plasma exchange in patients presenting with alveolar hemorrhage, and no differences in mortality or remission rates were observed. Thus, plasma",
            "recommend prescribing medications for prophylaxis to prevent P jirovecii pneumonia. Prophylaxis to prevent P jirovecii pneumonia is discussed above in the GPA/MPA recommendations. The same considerations regarding prophylaxis to prevent this condition in patients with GPA/MPA apply to those with EGPA. DISCUSSION In this guideline, we present the first ACR/Vasculitis Foundation recommendations for the management of GPA, MPA, and EGPA. Although these recommendations provide a general guide for"
        ]
    }
]